[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pre-eclampsia-severe\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pre-eclampsia-severe":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,59,85,110],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":40,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":47,"lastUpdatePostDateStruct":48,"startDateStruct":51,"completionDateStruct":53,"leadSponsor":55,"locationsCount":58},"100613200","prior-study-pre-eclampsia-risk-in-oocyte-recipients-100613200",false,"NCT07263490","PRIOR Study (Pre-eclampsia Risk In Oocyte Recipients)","PRIOR Study (Pre-eclampsia Risk In Oocyte Recipients) - Investigating Matching, Biomarkers and Outcomes.","PRIOR","Inclusion Criteria:\n\n* Age \\> 18 years\n* BMI \\\u003C 35 kg\u002Fm2\n* Normal wet smear within the past three years\n* Both nulli- and multiparous\n* Singletons and multiple gestations\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years\n* BMI \\> 35 kg\u002Fm2\n* HIV\u002F hepatitis\n* Essential hypertension\n* Chronic kidney disease\n* Undiagnosed vaginal bleeding\n* Uterine malformations\n* Persisting ovarian cysts\n* Tumors in hypothalamus, pituitary, thyroid, or adrenal glands.\n* Previous breast cancer\n* Known BRCA 1 or 2 gene\n* Unregulated thyroid disease\n* Cardiovascular disease\n* Breast feeding\n* Present or previous chemotherapy\u002Fradiation therapy\n* Present or previous malignant disease\n* Smoking\n* Alcohol\u002Fdrug abuse","FEMALE","18 Years",{"count":20,"type":21},462,"ESTIMATED","OBSERVATIONAL","The aim of this prospective observational cohort study is to investigate the pathophysiological mechanisms behind and risk of pre-eclampsia in women pregnant after fertility treatment with oocyte donation. The participants are included in of of two cohorts. One includes women pregnant after oocyte donation whereas the other includes women pregnant after IVF treatment with autologous oocytes.\n\nParticipants will be followed throughout pregnancy with blood samples, blood pressure, clinical controls and ultrasound examinations. Clinical outcomes will be registered post-partum.",[25,26,27,28,29,30,31,32,33,34,35,36,37,38,39],"Pre-eclampsia","Oocyte Donation","Pre-Eclampsia; Complicating Pregnancy","Pre-Eclampsia; Mild","Pre-Eclampsia, Severe","Pre-eclampsia or Eclampsia With Pre-existing Hypertension","ART","Neonatal Morbidity","Neonatal Mortality","Placental Abruption","Gestational Diabetes","Preterm Labor","Post-partum Hemorrhage (PPH)","Intrauterine Growth Restriction (IUGR)","Hypertensive Disorders of Pregnancy",[25,41,31,42,43,44,45],"Preeclampsia","Gestational hypertension","Oocyte donation","Egg donation","Gamete donation","RECRUITING","2026-04-07",{"date":49,"type":50},"2026-04-13","ACTUAL",{"date":52,"type":50},"2024-10-21",{"date":54,"type":21},"2028-06-01",{"name":56,"class":57},"Copenhagen University Hospital, Hvidovre","OTHER",6,{"id":60,"slug":61,"hasResults":11,"nctId":62,"briefTitle":63,"officialTitle":64,"acronym":4,"eligibilityCriteria":65,"healthyVolunteers":66,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":67,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":69,"conditions":70,"keywords":72,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":84},"100626024","finger-plethysmography-to-predict-fluid-responsiveness-in-healthy-pregnancy-and-severe-preeclampsia-100626024","NCT07430254","Finger Plethysmography to Predict Fluid Responsiveness in Healthy Pregnancy and Severe Preeclampsia","Finger Plethysmographic Cardiac Output Monitoring to Predict Fluid Responsiveness in Healthy Pregnancy and Women Diagnosed With Preeclampsia and Severe Features","Inclusion Criteria:\n\n* Women diagnosed with preeclampsia with severe features following ACOG recommendations (systolic\u002Fdiastolic BP \\>160\u002F110 mmHg, proteinuria, or other severe features like headaches, visual disturbances, kidney\u002Fliver impairment, thrombocytopenia).\n* Healthy pregnant women at term (for comparison group, e.g., scheduled for elective Cesarean delivery).\n\nExclusion Criteria:\n\n* Patients who can not provide written consent to participate in the study\n* BMI greater than 40 kg\u002Fm²\n* Multiple pregnancy (twins, triplets, etc.)\n* Non-reassuring fetal heart tracing\n* ≤ 22 weeks gestation\n* History of chronic arterial hypertension\n* Chronic kidney disease\n* Congenital or known acquired heart disease\n* Chronic obstructive pulmonary disease\n* Diabetes\n* History of stroke\n* Not tolerating passive leg raising (unable to be placed in the required study position)\n* No TTE-windows\n* Withdrawing consent\n* Emergency cesarean delivery",true,{"count":68,"type":21},88,"The goal of this observational study is to determine whether noninvasive finger plethysmographic cardiac output monitoring can help predict fluid responsiveness in pregnant women, including those with preeclampsia with severe features.\n\nThe main questions it aims to answer are :\n\n* Can changes in cardiac output measured by finger plethysmography predict fluid responsiveness?\n* How does this method perform compared with standard echocardiographic assessment? Participants will provide consent and undergo noninvasive hemodynamic monitoring and a brief reversible physiological challenge.",[29,71],"Pregnancy",[73],"Fluid responsiveness","NOT_YET_RECRUITING","2026-02-18",{"date":77,"type":50},"2026-02-24",{"date":79,"type":21},"2026-07-01",{"date":81,"type":21},"2028-07-01",{"name":83,"class":57},"Stanford University",1,{"id":86,"slug":87,"hasResults":11,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":4,"eligibilityCriteria":91,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":92,"enrollmentInfo":93,"targetDuration":4,"studyType":95,"phases":96,"briefSummary":98,"conditions":99,"keywords":4,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":4},"100560688","a-feasibility-study-to-evaluate-the-safety-of-the-knp-1000-apheresis-system-in-severe-preeclampsia-100560688","NCT06580405","A Feasibility Study to Evaluate the Safety of the KNP-1000 Apheresis System in Severe Preeclampsia","A Feasibility Study to Evaluate the Safety of the KNP-1000 Apheresis System in Patients With Preeclampsia With Severe Features","Inclusion Criteria:\n\nA participant is deemed suitable for inclusion in the investigation if she meets the following criteria:\n\n1. Pregnant woman ≥ 23 0\u002F7 and \\< 32 0\u002F7 weeks gestation, aged 18 to 45 years, hospitalized for preeclampsia at time of enrollment.\n2. Severe hypertension ever defined by resting systolic BP ≥ 160 mm Hg and\u002For diastolic BP ≥ 110 mm Hg on two occasions measured at least 4 hours apart.\n3. Proteinuria, defined as ≥ 300 mg protein in a 24-hour urine collection or ≥ 0.3 protein\u002Fcreatinine ratio.\n4. Provision of signed and dated informed consent form.\n\nExclusion Criteria:\n\nA participant will be excluded from the investigation if any of the following maternal or fetal criteria are met.\n\nMaternal Exclusion Criteria:\n\n1. Documented history of chronic hypertension, defined as systolic BP ≥ 140mmHg and\u002For systolic BP ≥ 90 mmHg before pregnancy or prior to 20 weeks of gestation.\n2. Documented history of proteinuria prior to pregnancy or prior to 20 weeks of gestation.\n3. Taking any form of angiotensin cascade blocker or angiotensin-converting enzyme (ACE) inhibitor at time of enrollment.\n4. Documented history of cardiac impairments including uncontrolled arrhythmia, unstable angina, decompensated congestive heart failure, or valvular disease.\n5. Actively receiving therapeutic anticoagulation therapy or within the therapeutic window after ceasing anticoagulation therapy at the time of enrollment.\n6. Any condition which, in the opinion of the Investigator, would necessitate immediate delivery within 24 hours.\n7. Signs or history of cerebral nervous system dysfunction, including seizures, cerebral edema (previously confirmed by computed tomography scan or magnetic resonance imaging per medical records).\n8. Confirmed or suspected diagnosis of pulmonary edema at time of enrollment.\n9. Diagnosis of HELLP syndrome.\n10. Thrombocytopenia (platelet count \\< 100,000\u002Fmm3) at time of enrollment.\n11. Anemia defined as hemoglobin \\< 8 g\u002FdL at time of enrollment.\n12. Absent or reverse flow on umbilical Doppler ultrasound exam at the time of screening, or documented history of negative or reverse flow during the current gestation period.\n13. Diagnosis of placenta previa during the current gestation period.\n14. Preterm labor at or before time of screening.\n15. Documented medical history of active hepatitis B virus, hepatitis C virus (HCV), syphilis, tuberculosis infection, or human immunodeficiency virus (HIV) positive status.\n16. Any condition that the Investigator deems a risk to the study participant or fetus in completing the investigation.\n17. Hypersensitivity to dextran sulfate cellulose or heparin.\n18. Multiple gestation.\n19. Documented history of familial hypercholesterolemia.\n20. Suspicion or diagnosis of placental abruption during the current gestation.\n21. Patients who have received the drug treatment not recommended by the American College of Obstetricians and Gynecologists (ACOG) practice bulletin Gestational Hypertension and Preeclampsia (the clinical management guidelines) within 6 months prior to enrollment.\n22. Patients who have participated in another clinical trial within 6 months prior to enrollment.\n\nFetal Exclusion Criteria:\n\n1. Documented record of chromosomal anomalies.\n2. Identifiable structural fetal abnormalities present at time of screening or a record of such abnormalities prior to enrollment.\n3. Oligohydramnios, defined as Amniotic fluid index (AFI) less than 5 cm when measured using the four-quadrant method at time of enrollment.\n4. Fetal growth restriction (FGR) defined as estimated fetal weight (EFW) below the 5th percentile for gestational age.","45 Years",{"count":94,"type":21},13,"INTERVENTIONAL",[97],"NA","The study will primarily evaluate safety of the KNP-1000 apheresis system for pregnant women and their fetuses diagnosed with preeclampsia with severe features between 23- and 32-weeks' gestation (very preterm).",[29],"2025-03-03",{"date":102,"type":50},"2025-03-05",{"date":104,"type":21},"2025-05-31",{"date":106,"type":21},"2028-06-30",{"name":108,"class":109},"Kaneka Medical America LLC","INDUSTRY",{"id":111,"slug":112,"hasResults":11,"nctId":113,"briefTitle":114,"officialTitle":115,"acronym":116,"eligibilityCriteria":117,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":118,"targetDuration":120,"studyType":22,"phases":4,"briefSummary":121,"conditions":122,"keywords":123,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":130,"startDateStruct":132,"completionDateStruct":134,"leadSponsor":136,"locationsCount":84},"100561273","prevalence-of-blood-pressure-complications-during-cesarean-section-in-pre-eclamptic-patients-hope-100561273","NCT06588023","Prevalence of Blood Pressure Complications During Cesarean Section in Pre-eclamptic Patients (HOPE)","Prevalence of Blood Pressure Complications During Cesarean Section in Pre-eclamptic Patients","HOPE","Inclusion Criteria:\n\n* Pre-eclamptic patient according to the criteria defined by SFAR 2020.\n* Indication of organised or semi-urgent cesarean section (Green or Orange code).\n* Adult patient, benefiting from a social security system.\n* Oral non-opposition to participation in the study.\n\nExclusion Criteria:\n\n* Urgent Cesarean (Red code).\n* Patient refusal.\n* Patient does not understand French.\n* Individual protection measures : guardianship, curatorship.",{"count":119,"type":21},80,"1 Day","Preeclampsia (PE) is an obstetric placental vascular pathology with a prevalence of 2 to 5% of pregnant women. It is defined by learned societies by the association of high blood pressure (BP≥140\u002F90mmHg) and proteinuria \\> 0.3g\u002Fday. The last French Maternal Mortality Report 2024 places cardiovascular complications among the main causes of maternal death. PE has an increasing number of deaths in 2016-2018 and significant preventability (66%).\n\nCesarean sections in pre-eclamptic patients are difficult procedures and, do not benefit from any specific recommendations. Cesarean section is promptly performed under regional anesthesia by spinal anesthesia or spinal anesthesia with combined epidural, techniques that cause maternal arterial hypotension with consequences for the baby.\n\nThese hypertensive patients, often on antihypertensives, challenge the anesthesiologist to manage the hemodynamic balance between the risk of arterial hypotension generated by the anesthesia corrected by vasoactive amines and the risk of major hypertension secondary to their management. The major risk in these patients with low platelet counts is hemorrhagic stroke.\n\nOur study is an observational, bi-centric study between the maternity wards of the Clermont Ferrand and Lille University Hospitals.\n\nIt consists of collecting data prospectively on all pre-eclamptic patients undergoing a non-urgent cesarean section.\n\nThe objective is to observe the management of hemodynamics and calculate the prevalence of complications such as maternal hypotension and\u002For hypertension through the implementation of non-invasive monitoring (ClearSight).\n\nPatients meeting the inclusion and non-inclusion criteria may be included in the study by an investigator after having given a non-opposition agreement after having received clear and fair information about the study.\n\nIn any case, the care of patients participating in the study will not be modified in any way compared to the usual practices of the services.",[25,29],[124,125,126,127,128],"cesarean section","Blood pressure complications","pre-eclampsia","hypertension","hypotension","2024-09-06",{"date":131,"type":50},"2024-09-19",{"date":133,"type":21},"2024-09-05",{"date":135,"type":21},"2025-09",{"name":137,"class":57},"University Hospital, Clermont-Ferrand"]